characteristics.text: ERC000011
characteristics.characteristic: ENA-CHECKLIST
characteristics.text: 2022-05-12T12:16:29Z
characteristics.characteristic: ENA-FIRST-PUBLIC
characteristics.text: 2022-05-12T12:16:29Z
characteristics.characteristic: ENA-LAST-UPDATE
characteristics.text: SAMEA13318679
characteristics.characteristic: External Id
characteristics.text: Klinikum rechts der Isar (TUM)
characteristics.characteristic: INSDC center name
characteristics.text: 2022-05-12T12:16:29Z
characteristics.characteristic: INSDC first public
characteristics.text: 2022-05-12T12:16:29Z
characteristics.characteristic: INSDC last update
characteristics.text: public
characteristics.characteristic: INSDC status
characteristics.text: ERS10921418
characteristics.characteristic: SRA accession
characteristics.text: Cell line PSN1 JNJ-64619178 20nM t=72h Replicate 3
characteristics.characteristic: Submitter Id
characteristics.text: PSN1
characteristics.characteristic: cell line
characteristics.text: human pancreatic ductal adenocarcinoma cell
characteristics.characteristic: cell type
characteristics.text: human
characteristics.characteristic: common name
characteristics.text: human pancreatic ductal adenocarcinoma cell with high levels of MYC treated with PRMT5 inhibitor JNJ-64619178 for 72 hours or control
characteristics.characteristic: description
characteristics.text: human pancreatic ductal adenocarcinoma
characteristics.characteristic: isolation source
characteristics.text: Homo sapiens
characteristics.characteristic: organism
characteristics.text: Homo sapiens
characteristics.characteristic: scientific_name
characteristics.text: Pancreas
characteristics.characteristic: tissue type
characteristics.text: RNA-seq Data of human pancreatic ductal adenocarcinoma cell with high levels of MYC treated with PRMT5 inhibitor JNJ-64619178 for 72 hours or control
characteristics.characteristic: title